Enviaments recents

ESMO Podcast on upper gastrointestinal cancers—highlights in biliary and pancreatic cancers from ASCO 2025

Dekervel, Jeroen; Castet, Florian; Vogel, Arndt (Data de publicació: 2025-10-20)

Podcast; Upper gastrointestinal cancers; Biliary and pancreatic cancers

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

de Melo Gagliato, Debora; Buzaid, Antonio C; Perez-Garcia, Jose Manuel; Llombart-Cussac, Antonio; Cortés Castan, Javier (Data de publicació: 2021-08-26)

Inhibidors de CDK4/6; Càncer de mama amb receptor hormonal positiu; Càncer de mama metastàtic

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Griesinger, Frank; Thomas, M.; Baik, Christina; Tan, Daniel S. W.; Garralda Cabanas, Elena; Subbiah, Vivek; Curigliano, Giuseppe (Data de publicació: 2022-11-28)

RET inhibition; Pralsetinib; Targeted therapy

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Schöfski, Patrick; Heinrich, Michael C.; Bauer, Sebastian; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (Data de publicació: 2022-12-28)

Alopecia; Quality of life; Ripretinib

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2—Ex vivo imaging: Added value and acquisition

Ianus, Andrada; Hansen, Brian; Barrett, Rachel Laura Coopersmith; Schilling, Kurt; Grussu, Francesco; Howard, Amy (Data de publicació: 2025-05-26)

Diffusion MRI; Diffusion tensor; Ex vivo

Multi-echo quantitative susceptibility mapping: how to combine echoes for accuracy and precision at 3 Tesla

Biondetti, Emma; Karsa, Anita; Battiston, Marco; Yiannakas, Marios; Thomas, David L.; Shmueli, Karin; Grussu, Francesco (Data de publicació: 2022-09-13)

MRI; Multi-echo QSM; Quantitative susceptibility mapping

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis

Cortés Castan, Javier; Twelves, Chris (Data de publicació: 2021-10-22)

Càncer de mama avançat; Eribulina; Supervivència global

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

Vitiello, Pietro Paolo; BARDELLI, Alberto; Saoudi Gonzalez, Nadia (Data de publicació: 2025-03-06)

Colorectal cancer; Drug resistance; Precision medicine

Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells

Mayer, Isabella; Doma, Eszter; Klampfl, Thorsten; Prchal-Murphy, Michaela; Kollmann, Sebastian; Schirripa, Alessia; Malumbres, Marcos (Data de publicació: 2024-07-18)

Inactivated CDK6; Hematopoietic stem cells

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

Mutch, David; Voulgari, Athina; Chen, Xian (Marissa); Bradley, William; Pérez-Fidalgo, J. Alejandro; OAKNIN, ANA (Data de publicació: 2024-05-31)

MEK inhibitor; PARP Inhibitor; Ovarian cancer

Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer

Rubio-Perez, Carlota; Gonzalez-Roca, Eva; Seguí, Elia; Angelats, Laura; Paré, Laia; Sanfeliu Torres, Esther; Villacampa Javierre, Guillermo; Vivancos, Ana (Data de publicació: 2025-04-01)

Breast cancer; Immune gene expression; Longevity

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Bauer, Sebastian; Heinrich, Michael C.; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (Data de publicació: 2022-06-27)

Ripretinib; Mutacions; Neoplàsies gastrointestinals

ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study

Monti, Manuela; Degenhardt, Tom; Brain, Etienne; Wuerstlein, Rachel; Argusti, Alessandra; Puntoni, Matteo; Cortés Castan, Javier; Piris-Giménez, Alejandro (Data de publicació: 2022-07-19)

Academic; Radiopharmaceuticals; Regulatory in Europe

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Yu, Evan; Piulats, Josep M.; Fong, Peter C.C.; Todenhöfer, Tilman; Laguerre, Brigitte; Carles Galceran, Joan; Gravis, Gwenaelle (Data de publicació: 2023-02-21)

Metastatic castration-resistant prostate cancer; Olaparib; Pembrolizumab

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

STRADELLA, AGOSTINA; Johnson, Melissa L.; GOEL, SANJAY; Park, Haeseong; Saavedra, Omar; Lakhani, Nehal; Arkenau, Hendrik-Tobias (Data de publicació: 2024-07-11)

DNA repair; Biomarkers; Target therapy

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

Turpin, Anthony; Delliaux, Carine; Pauline, PARENT; Chevalier, Hortense; Escudero Iriarte, Carmen; Bonardi, Franck; Querol, Jessica; Herranz Martín, Nicolás; TIAN, TIAN (Data de publicació: 2023-12-20)

Endocrine cancer

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy

Pardo Aranda, Nuria; Martinez Marti, Alexandre; Assaf-Pastrana, Juan David; cedres, susana; Valdivia Bustamante, Augusto; Iranzo, Patricia; Callejo, Ana; NAVARRO, ALEJANDRO; FELIP, ENRIQUETA (Data de publicació: 2024-01-16)

Biomarkers; Immunotherapy; Malignant pleural mesothelioma

Antibody-drug conjugates combinations in cancer treatment

Pretelli, Giulia; Mati, Kleida; Motta, Lucia; STATHIS, ANASTASIOS (Data de publicació: 2024-07-12)

Antibody-drug conjugates; Combination regimens; Novel anticancer therapies

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Martínez Martín, Sandra; Alonso-Casal, Guzman; Arqués, Oriol; GARRALDA, Elena; Beaulieu, Marie-Eve; Casacuberta-Serra, Sílvia; Foradada Felip, Laia; Perez-Lopez, Raquel; Whitfield, Jonathan; Soucek, Laura; Moreno, Victor (Data de publicació: 2024-03-27)

MYC; Solid tumors

Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer

Wang, Kang; Zerdes, Ioannis; Johansson, Henrik; Sarhan, Dhifaf; Sun, Yizhe; Kanellis, Dimitrios; Mezheyeuski, Artur (Data de publicació: 2024-05-15)

Immunometabolism; Breast cancer

Articles científics - VHIO: Enviaments recents

ESMO Podcast on upper gastrointestinal cancers—highlights in biliary and pancreatic cancers from ASCO 2025 ﻿

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge ﻿

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial ﻿

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial ﻿

Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2—Ex vivo imaging: Added value and acquisition ﻿

Multi-echo quantitative susceptibility mapping: how to combine echoes for accuracy and precision at 3 Tesla ﻿

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis ﻿

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer ﻿

Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells ﻿

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer ﻿

Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer ﻿

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study ﻿

ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study ﻿

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study ﻿

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors ﻿

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor ﻿

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy ﻿

Antibody-drug conjugates combinations in cancer treatment ﻿

MYC targeting by OMO-103 in solid tumors: a phase 1 trial ﻿

Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer ﻿